Asthma and chronic obstructive pulmonary disease (COPD) are two distinct, chronic, inflammatory respiratory diseases.1,2 Asthma develops early in life, mainly in atopic individuals, and is characterised by airway hyper-responsiveness and recurrent wheezing due to a chronic inflammation of the airways caused by a CD4, T-helper type-2, eosinophilic inflammation.1 COPD develops later in life (age >40 years), in smokers, and is characterised by progressive irreversible airflow obstruction, chronic respiratory symptoms, and chronic inflammation of the airways and the lung caused by a CD8, Tc1, neutrophilic inflammation.
Benralizumab: for asthma, not yet for COPD / Fabbri, Leonardo. - In: THE LANCET RESPIRATORY MEDICINE. - ISSN 2213-2600. - STAMPA. - 2:11(2014), pp. 862-863. [10.1016/S2213-2600(14)70225-5]
Benralizumab: for asthma, not yet for COPD
FABBRI, Leonardo
2014
Abstract
Asthma and chronic obstructive pulmonary disease (COPD) are two distinct, chronic, inflammatory respiratory diseases.1,2 Asthma develops early in life, mainly in atopic individuals, and is characterised by airway hyper-responsiveness and recurrent wheezing due to a chronic inflammation of the airways caused by a CD4, T-helper type-2, eosinophilic inflammation.1 COPD develops later in life (age >40 years), in smokers, and is characterised by progressive irreversible airflow obstruction, chronic respiratory symptoms, and chronic inflammation of the airways and the lung caused by a CD8, Tc1, neutrophilic inflammation.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
